Aptose Biosciences Inc. Quarterly report [Sections 13 or 15(d)]

Quarterly report [Sections 13 or 15(d)]

Note 11 - Share Capital (Details Textual)

Note 11 - Share Capital (Details Textual) - USD ($)									3 Months Ended		11 Months Ended	18 Months Ended
Note 11 - Share Capital (Details Textual) - USD ($)	Feb. 12, 2025	Feb. 07, 2025	Nov. 25, 2024	Sep. 11, 2024	Jun. 03, 2024	Jan. 30, 2024	Sep. 06, 2023	May 25, 2023	Mar. 31, 2025	Mar. 31, 2024	Apr. 30, 2024	May 30, 2024	Feb. 03, 2025	Dec. 31, 2024	Sep. 30, 2024	Sep. 05, 2024	Apr. 01, 2024	Dec. 31, 2023	Aug. 10, 2023	Dec. 09, 2022	Nov. 04, 2021
Nasdaq Listing Rule, minimum requirement for stockholders' equity									$ 2,500,000
Negative shareholder's equity									$ (7,393,000)	$ 137,000				$ (4,543,000)				$ (2,901,000)
Common Stock, Shares Outstanding									2,552,429					2,006,028
Warrants outstanding									1,267,585					1,267,585
Common Shares [Member]
Negative shareholder's equity									$ 459,771,000	$ 450,485,000				$ 457,404,000				$ 444,806,000
Hanmi Pharmaceuticals Co Ltd [Member]
Issuance of common shares under the ESPP share purchase							$ 3,000,000
Shares Issued, Price Per Share (in dollars per share)									$ 51.3
Warrants to purchase common shares, number of warrants									77,972
Number of common shares held									508,710												7,190
Hanmi Pharmaceuticals Co Ltd [Member] \| Common Shares [Member]
Number of shares sold							22,281
Maximum [Member] \| Hanmi Pharmaceuticals Co Ltd [Member]
Investment for ownership interest																			$ 7,000,000
Percentage of investment																			19.99%
2023 Committed Equity Facility [Member]
Stock issuance program authorized shares								838
Common shares issued (in shares)										336
2023 Committed Equity Facility [Member] \| Keystone [Member]
Common shares issued (in shares)											41,019
Issuance of common shares under the ESPP share purchase											$ 2,800,000
Stock Issuance Program, Authorized Amount								$ 25,000,000
Percentage of common shares outstanding.								19.99%									19.99%
Shares Issued, Price Per Share (in dollars per share)											$ 68.1
Financing costs including underwriting costs, professional fees and recognition of deferred financing costs											$ 168,000,000
2023 Committed Equity Facility [Member] \| Initial Commitment Shares [Member]
Common shares issued (in shares)								251
Stock Issuance, Percent of Cash Commission to Broker								30.00%
2023 Committed Equity Facility [Member] \| First Back-End Commitment Shares [Member]
Common shares issued (in shares)								251
Stock Issuance, Percent of Cash Commission to Broker								30.00%
2023 Committed Equity Facility [Member] \| Commitment Shares [Member] \| Keystone [Member]
Common shares issued (in shares)											838
The 2022 ATM Offering [Member]
Issuance of common shares under the ESPP share purchase												$ 2,000,000
Stock Issuance Program, Authorized Amount																				$ 50,000,000
Proceeds from Issuance of Common Stock, Gross												$ 2,000,000
Stock Issuance, Percent of Cash Commission to Broker															3.00%
Cash proceeds from issuing shares									$ 828,000
Private Placement [Member]
Proceeds from Issuance of Common Stock, Gross						$ 4,000,000
Private Placement [Member] \| Series A Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights					$ 34.5
Warrants, Remaining contractual life					5 years
Warrants to purchase common shares, exchange price					$ 34.5
Private Placement [Member] \| Series B Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights					34.5
Warrants to purchase common shares, exchange price					$ 34.5
Warrants, maturity date					Mar. 05, 2026
Private Placement [Member] \| Hanmi Pharmaceuticals Co Ltd [Member]
Common shares issued (in shares)						70,175
Shares Issued, Price Per Share (in dollars per share)						$ 57
Class of Warrant or Right, Exercise Price of Warrants or Rights						51.3
Warrants to purchase common shares, exchange price						$ 51.3
Warrants, maturity date						Jan. 31, 2029
Cash transaction costs						$ 300,000
Private Placement [Member] \| Hanmi Pharmaceuticals Co Ltd [Member] \| Common Shares [Member]
Warrants to purchase common shares, number of warrants						77,972
Private Placement [Member] \| Maximum [Member] \| Series A Warrants [Member]
Warrants to purchase common shares, number of warrants					128,500
Private Placement [Member] \| Maximum [Member] \| Series B Warrants [Member]
Warrants to purchase common shares, number of warrants					128,500
Public Offering [Member]
Common shares issued (in shares)						188,304
Class of Warrant or Right, Exercise Price of Warrants or Rights						$ 51.3
Warrants to purchase common shares, exchange price						$ 51.3
Proceeds from Issuance of Common Stock, Gross						$ 9,700,000
Warrants, maturity date						Jan. 30, 2029
Cash transaction costs						$ 1,600,000
Public Offering [Member] \| Common Shares [Member]
Warrants to purchase common shares, number of warrants						188,174
Public Offering [Member] \| Newbridge Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights						$ 64.13
Warrants to purchase common shares, exchange price						64.13
Public Offering [Member] \| Newbridge Warrants [Member] \| Common Shares [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights						18,084
Warrants to purchase common shares, exchange price						$ 18,084
Public Offering [Member] \| Hanmi Pharmaceuticals Co Ltd [Member]
Premium share price (as a percent)						11.00%
Over-Allotment Option [Member]
Common shares issued upon exercise of stock options						$ 24,561
Shares Issued, Price Per Share (in dollars per share)						$ 51.3
2025 Committed Equity Facility [Member] \| Maximum [Member]
Stock Issuance Program, Authorized Amount		$ 25,000,000
Amount agreed to pay for reasonable expenses under purchase agreement		$ 25,000,000
2025 Committed Equity Facility [Member] \| Commitment Shares [Member]
Stock issuance program authorized shares		8,020
The 2025 ATM Offering [Member]
Common shares issued (in shares)	137,000
Issuance of common shares under the ESPP share purchase	$ 800,000
Stock Issuance Program, Authorized Amount													$ 1,000,000
Shares Issued, Price Per Share (in dollars per share)	$ 7.31
Proceeds from Issuance of Common Stock, Gross	$ 1,000,000
Stock Issuance, Percent of Cash Commission to Broker													3.00%
November 2024 Public Offering [Member]
Number of shares sold			1,333,333
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 6
Warrants, Remaining contractual life			5 years
Professional fees			$ 500,000
Warrants to purchase common shares, exchange price			$ 6
Proceeds from Issuance of Common Stock, Gross			$ 8,000,000
Sale of stock price per share			$ 6
Transaction cost including placement agent fees and professional fees			$ 1,100,000
Placement agent fees			$ 600,000
November 2024 Public Offering [Member] \| Alliance Global Partners [Member]
Warrants issued			53,333
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 8.25
Warrants, Remaining contractual life			5 years
Warrants to purchase common shares, exchange price			$ 8.25
November 2024 Public Offering [Member] \| Maximum [Member]
Warrants to purchase common shares, number of warrants			666,599
September 2024 Common Share Issuance [Member]
Common shares issued (in shares)				68,500
Pre-Funded warrants exercised				68,500
Cash proceeds				$ 2,000,000
Class of Warrant or Right, Exercise Price of Warrants or Rights				$ 0.03
Percentage of shares outstanding																20.00%
Warrants to purchase common shares, exchange price				$ 0.03
Registered Direct Offering [Member]
Number of shares sold					60,000
Shares Issued, Price Per Share (in dollars per share)									$ 34.5
Proceeds from Issuance of Common Stock, Gross					$ 4,400,000
Cash transaction costs					$ 400,000
Registered Direct Offering [Member] \| H.C. Wainwright [Member]
Warrants issued					6,423
Class of Warrant or Right, Exercise Price of Warrants or Rights					$ 43.13
Warrants to purchase common shares, exchange price					$ 43.13
Warrants, maturity date					Jun. 03, 2029
Registered Direct Offering [Member] \| Pre-Funded Warrants [Member]
Warrants issued					68,500
Class of Warrant or Right, Exercise Price of Warrants or Rights					$ 0.03
Warrants to purchase common shares, exchange price					$ 0.03
Warrants, maturity date					Jun. 25, 2029